Cannabis Stock News- Investing in Cannabis and Hemp Stocks

Wednesday, November 4, 2020

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 491- #Marijuana Wins Big in #USElection

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 491- #Marijuana Wins Big in #USElection

Delta, Kelowna, BC, November 4, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2020/110420-StocksToWatch.mp3

Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/11041Wins-Big-US-Election.asp

Hear the investor ideas potcast on Spotify

Hear Investor ideas cannabis potcast on iTunes

Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today’s podcast we will be looking at the many states that voted in favour of cannabis legalization in yesterday’s election.

New Jersey voters have approved a constitutional ballot initiative to legalize marijuana for adults 21 and over and establish a framework for marijuana regulation in the Garden State. New Jersey becomes the 12th state to enact a legalization law.

“This is a great day for New Jersey. After years of political inaction, voters have definitively approved marijuana legalization,” said Steve Hawkins, executive director of the Marijuana Policy Project, which was founded in 1995 and has played a central role in 10 state-level legalization victories over the past eight years.

“The passage of this ballot measure positions New Jersey to take the lead in the Northeast and will push neighboring states, like New York and Pennsylvania, to take action on marijuana legalization,” Hawkins added. “This is a victory for social justice given that Black residents of New Jersey are 3.5 times more likely to be arrested for marijuana than white residents despite similar usage rates.”

New Jersey is one of five states that voted on marijuana reform ballot initiatives this November. In Arizona, New Jersey, and Montana, there were ballot initiatives to legalize marijuana for adults 21 and over which were all passed.

Chief Executive Officer Steve White of Harvest Health and Recreation Inc. (CSE: HARV) commented, "The recreational initiative in Arizona represents a well-rounded approach to allow the expansion of access to cannabis in Arizona. We fully expect the implementation of Prop 207 will positively impact tax revenue and social justice in Arizona, while strengthening employer protections and enhancing public safety. As the largest operator of medical dispensaries in the state, we look forward to serving recreational customers under this new program."

White continued, "The legalization of recreational cannabis continues to gain public support and becomes more mainstream as more people are positively affected directly themselves or know others who benefit from the availability of regulated and legal cannabis. We are proud to have played a role in the advancement of legal cannabis in our home state of Arizona. We appreciate the support of state, local and community officials and the ongoing efforts by the Arizona Department of Health Services to make our medical and recreational markets a model for other markets across the country."

In Mississippi voters have approved a constitutional ballot initiative to establish a medical marijuana program for patients with debilitating conditions. Mississippi becomes the 36th state to enact a medical marijuana law.

“It is great to see that the tides of change are continuing to flow across the country and now they have come to Mississippi,” said Steve Hawkins, executive director of the Marijuana Policy Project, which was founded in 1995 and has played a central role in eight state-level legalization victories over the past eight years. “As we saw in Utah in 2018, and as we see in Mississippi this year, medical marijuana can pass in any state in the country.”

In South Dakota voters approved proposals to legalize both medical and recreational marijuana, a major shift after the state overwhelmingly rejected a medical pot measure four years ago.

And in Oregon, voters made history by passing the first state law in the US to decriminalize possession of hard drugs including heroin, cocaine and LSD. The measure backed by criminal justice reform groups is aimed at diverting people from jails and prisons by treating possession as a citation and expanding access to treatment and recovery.

The Oregon drug initiative will allow people arrested with small amounts of hard drugs to avoid going to trial, and possible jail time, by paying a $100 fine and attending an addiction recovery program. The treatment centers will be funded by revenues from legalized marijuana, which was approved in Oregon several years ago.

“Today’s victory is a landmark declaration that the time has come to stop criminalizing people for drug use,” said Kassandra Frederique, the executive director of the Drug Policy Alliance, which backed the measure.

Oregon voters also approved a measure making it the first state to legalize the therapeutic use of psychedelic mushrooms.

Heading into Election Day, 11 states had legalized marijuana for adults 21 and over, and 34 states had legalized medical marijuana.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

Tuesday, November 3, 2020

Investorideas.com - Cannabis Stock News: Supreme Cannabis (TSX: FIRE) (OTCQX: SPRWF) Schedules First Quarter 2021 Financial Results Release and Conference Call

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 490 (TSX: $DN.TO) (OTCQX: $VRNDF) (NASDAQ: $GWPH) (NASDAQ: $VFF) (TSX: $VFF.TO)

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 490 (TSX: $DN.TO) (OTCQX: $VRNDF) (NASDAQ: $GWPH) (NASDAQ: $VFF) (TSX: $VFF.TO)

Today's podcast sponsored by Cannabis Suisse Corp. (OTC: $CSUI), a fully licensed cannabis cultivation and distribution company in Switzerland

Delta, Kelowna, BC, November 3, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2020/110320-StocksToWatch.mp3

Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/11031DN-VRNDF-GWPH-VFF.asp

Hear Investor ideas cannabis potcast on iTunes

Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

Today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's facilities for producing cannabis are based in Dietikon, Switzerland, and contain the art surveillance equipment to enable an around the clock webcast. Cannabis Suisse grows high quality, organic cannabis with sustainable, all-natural principles. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse proprietary trademarked MoldStandard is a quantitative microbiology method for analyzing yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary trademarked CannaMec is a method for quantifying and removing residual solvents during packaging and storage of CBD products. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.

In today’s podcast we look at a few public and private company announcements.

Pure Extracts Technologies Corp., a plant-based extraction company focused on cannabis, hemp, and functional mushroom sectors, announced that the company’s stock will commence trading on the Canadian Securities Exchange (“CSE”) under the symbol “PULL” on November 5, 2020.

“There currently is a tremendous consumer demand for natural health products with the ability to immediately enhance our quality of life. With Health Canada officially granting Pure Extracts a Standard Processing License under the Cannabis Act, this has put us on a path to deliver full-spectrum oil products by the end of Q4, 2020” said chief executive officer Ben Nikolaevsky. “Our trading debut on the CSE is another vote of confidence in our ability to effectively meet the needs of consumers focused on receiving cannabis, hemp and functional mushroom products.”

Pure Extracts would like to thank its expert tradespeople who worked tirelessly on the its state-of-the-art facility in Pemberton, BC, its team of dedicated employees, and the investors who have financed the company for a total $9.45MM CAD allowing it to become a world-class, plant-based extraction company.

Pure Extracts was incorporated under the BCBCA and has its offices and operations in Pemberton, British Columbia. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act. Pure Extracts is undertaking the operations of toll processing, white labelling, and developing its own private label of products incorporating its full spectrum THC and CBD based extracted oils.

Additionally, Pure Extracts is presently expanding its business to include functional mushrooms extraction by working on functional mushroom extraction processes compatible with its existing infrastructure. Pure Extracts has a fully built CO₂ extraction facility built to European Union GMP standards and intends to seek EU GMP certification of its operations allowing it to export its products for sale in Europe where such products are legal.

DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: VRNDF) announced that it has now surpassed one million transactions through its retail cannabis stores since legalization of recreational cannabis use. The Company opened its first “Delta 9 Cannabis Store” on October 17, 2018 and has since grown its retail store footprint to seven operating stores in the Manitoba and Alberta markets.

In addition to achieving the milestone number of transactions, the Company is pleased to provide the following statistics in connection with its retail cannabis business;

● Over 1,000,000 in-store and online transactions

● Over $50 Million in-store and online retail revenues

● Average transaction size of $50.20 per transaction

● Over 1.5 Million unique website visitors to delta9.ca

● Over 17,000 square feet of retail store space averaging $2,021 in revenue per square foot per year.

● Average Gross Profit margin of approximately 26%

"We are very pleased with the revenue growth generated from our retail stores since legalization in 2018," said John Arbuthnot, CEO of Delta 9. “Delta 9 has stayed focused on its strategy to vertically integrate into the retail segment and leveraging its retail business as a means to facilitate distribution of Delta 9 branded products directly to Canadian consumers.”

Management believes that there are a number of benefits to pursuing a vertical integration strategy into retail sales including:

● Control over a direct to consumer sales force and product distribution;

● Control over direct to consumer branding and marketing initiatives;

● Capturing additional revenues and gross margin from retail sales; and

● Direct feedback from consumers regarding product trends, marketing strategies, etc.

GW Pharmaceuticals plc (NASDAQ: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today announced that the Company has initiated the first U.S. Phase 3 clinical trial studying nabiximols for multiple sclerosis (MS)-associated spasticity.

Nabiximols, known as Sativex® outside of the U.S. and approved for use to treat MS spasticity in over 25 countries, is a complex botanical medicine formulated from extracts of the cannabis plant administered as an oral spray. Positive results from three previous European Phase 3 clinical studies show nabiximols was well-tolerated and provided continued reductions in patient-reported spasticity for individuals with MS.

This Phase 3 trial is one of five pivotal studies planned for nabiximols in MS spasticity, with the remaining studies on track to commence either later this year or in 2021. GW expects that a positive result in any one of these five studies will enable an NDA submission, potentially as early as mid- next year.

“We are excited that the U.S. Phase 3 clinical program evaluating nabiximols in Multiple Sclerosis spasticity is now recruiting patients, after a delay due to COVID-19. Given the rigorous studies already conducted on the medicine outside of the U.S., and positive discussions with the FDA, we believe that we have a clear path to an NDA submission, potentially as soon as next year, and a significant second product opportunity for GW in the U.S.,” stated Justin Gover, GW’s Chief Executive Officer. “Now is the ideal time to develop nabiximols in the U.S. as research shows a significant percentage of spasticity patients are today self-medicating using unapproved cannabis products to relieve their spasticity.”

“There is a significant need for new treatments to address spasticity in MS patients, a challenging condition with little therapeutic innovation in decades in the United States,” said Dr. Stephen Krieger, Associate Professor of Neurology at the Mount Sinai Hospital.

“Nabiximols has the potential to be a rigorously tested and FDA-regulated cannabis-derived medicine for people living with MS. I look forward to participating as an investigator in this study which will evaluate the effect of nabiximols on the frequency of muscle spasms.”

The study is a Phase 3, double-blind, parallel, placebo-controlled study that will evaluate the safety and efficacy of nabiximols for spasm frequency over a 12-week period and is expected to enroll 446 participants. The first patient is now screened and in baseline evaluation.

Beyond this initial study, the Company intends to commence the following additional Phase 3 trials of nabiximols for MS-associated spasticity:

● Phase 3 muscle tone studies – placebo-controlled cross-over design

○ N=52; Expected start: Q4 2020 (subject to COVID)

○ N=190; Expected start: Q1 2021

○ N=36 (nabiximols responders); Expected start: Q1 2021

● Phase 3 spasm frequency studies – placebo-controlled parallel group

○ N=~200 (nabiximols responders); Expected start: Q2 2021

Village Farms International, Inc. (NASDAQ: VFF) (TSX: VFF) announced it has completed the acquisition from Emerald Health Therapeutics, Inc. of 36,958,500 common shares of Pure Sunfarms Corp. owned by Emerald, representing approximately 41.3% of the issued and outstanding common shares of Pure Sunfarms. With the completion of the Pure Sunfarms Transaction, Village Farms now owns 100% of the common shares of Pure Sunfarms. The acquisition of the Pure Sunfarms shares will be immediately accretive to Village Farms' net income.

"Village Farms conceived of a joint venture to launch its Canadian cannabis business, and the result, Pure Sunfarms, is now one of the leading Canadian cannabis companies. With this transaction our shareholders will now fully benefit from our initiative," said Michael DeGiglio, CEO, Village Farms. "Pure Sunfarms is well positioned for long-term growth as one of what we believe will be just a small number of major suppliers to the Canadian cannabis market. Importantly, as part of the Village Farms organization Pure Sunfarms can now pursue additional opportunities to further leverage its success to date and increase its earnings potential. I am pleased to welcome the outstanding management team and employees of Pure Sunfarms to our organization, and welcome back so many Village Farms' personnel who transitioned to our cannabis venture in the early days to ensure that Pure Sunfarms would benefit fully from Village Farms' decades of experience and site-specific operational expertise. Pure Sunfarms' CEO, Mandesh Dosanjh, and his entire team have done exceptional work in bringing Village Farms' vision to reality, and we look forward to their continued contribution to its success as part of Village Farms going forward."

"The acquisition of the entirety of Pure Sunfarms is a defining moment for Village Farms, furthering our transformation to a vertically integrated, plant-based consumer packaged goods company. It allows us to fully leverage the invaluable cannabis expertise Village Farms has gained in combination with the organizational strength underlying the Village Farms produce business to pursue high-growth opportunities in emerging legal cannabis and CBD markets in the United States and targeted markets internationally. We will do so with the same thoughtfulness, prudence, strategic decision making and focus on near-term profitability and long-term return on invested capital that has been fundamental to the success of our investment in Pure Sunfarms."

"We especially look forward to the potential for U.S. regulatory changes that would permit us to pursue our U.S. cannabis aspirations. With one of the largest greenhouse footprints in the U.S., located in one of the best regions for growing in the country, alongside our cannabis success in Canada, we believe there is no company better positioned for long-term success in the U.S. cannabis industry. We are ready to move quickly and aggressively as soon as the regulatory environment permits."

Upon closing of the Pure Sunfarms Transaction, Pure Sunfarms will be fully consolidated in Village Farms' financial results. Village Farms will report its third quarter financial results and the third quarter financial results of Pure Sunfarms on November 13, 2020. Village Farms' financial results for the three and nine months ended September 30, 2020 will continue to reflect Village Farms' 58.7% ownership of Pure Sunfarms as an investment in a joint venture.

Once again, today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

Monday, November 2, 2020

Investorideas.com - Cannabis Stock News: Emerald Health Therapeutics (TSXV: EMH) Completes Sale of Pure Sunfarms Interest & Achieves Pivotal Milestone in Transforming its Business

Friday, October 30, 2020

Investorideas.com - Hemp Stock News: DGDM (OTC PINK: DGDM) Sees Expanding Opportunity in Hemp Processing, Product Development

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 489 - #Psychedelic Spotlight-(CSE: $SPOR.C) (OTC: $TRMNF) (NEO: MMED) (OTCQB: $MMEDF)

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 489 - #Psychedelic Spotlight-(CSE: $SPOR.C) (OTC: $TRMNF) (NEO: MMED) (OTCQB: $MMEDF)

Today's podcast sponsored by Cannabis Suisse Corp. (OTC: $CSUI), a fully licensed cannabis cultivation and distribution company in Switzerland

Delta, Kelowna, BC, October 30, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2020/103020-StocksToWatch.mp3

Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/10301SPOR-TRMNF-NMED-MMEDF.asp

Hear the investor ideas potcast on Spotify

Hear Investor ideas cannabis potcast on iTunes

Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today’s podcast we look at a few public and private company announcements focussing specifically on the emerging psychedelic sector.

NEW WAVE HOLDINGS CORP. (CSE: SPOR) (OTC:TRMNF) an investment issuer that provides capital and support services, announced it will bring Microdose to Vancouver November 1st - 10th to start production for the next phase of "The World on Drugs" documentary.

The team at New Wave is pleased to announce that Microdose is traveling to Vancouver from November 1-10th, to film the next phase of the upcoming documentary "The World on Drugs". The production aims to illuminate a bold commentary on drug policy, psychedelic medicine and mental health comes at a pivotal moment in our collective evolution. The sharp increase in opioid-related overdose deaths in B.C. highlight the urgent need for new treatments and policy, providing the unique opportunity to spotlight psychedelic medicine. We have scheduled interviews with leading experts in their respective fields, and would love to hear your suggestions for interview candidates, key locations, or critical subject matter that should be filmed in Vancouver, please fill out this open feedback/application form.

"We would like to thank New Wave Holdings for being our inaugural sponsor for this next phase of our international effort to document the intersection of mental health, psychedelic medicine and global drug policy around the world. We are committed to building a compelling, objective narrative by listening to the experts, this documentary will truly be a team effort." Microdose CEO - Patrick Moher

Pilot footage for "The World on Drugs" was captured in Mexico where the Microdose team met with notable thought leaders, clinicians and psychedelic medicine providers. For any general partnership inquiries, please reach out to Connor Haslem at: Connor@microdose.buzz.

"The Microdose team hopes to continue the journey by heading to Portugal, where full drug decriminalization provides fascinating insight into a potential, more progressive way forward. We also intend on going to Jamaica, another iconic location significantly impacted by the War on Drugs that is pioneering new mental health treatments. As our worldwide documentary filmmaking journey progresses, we hope to illuminate the potential of psychedelic medicine to disrupt the mental health crisis across the globe." - Patrick Moher continued.

The data form: If you or anyone you know wants to contribute or is interested to collaborate on this project, please fill out this form. We do have a limited filming period that is available, so unfortunately we won't be able to connect directly with all submissions-but, everybody that fills this form out on behalf of somebody or behalf of themselves will get a free copy of the completed film as a thank you gift for your contribution.

If you are interested in getting involved with this dynamic documentary filmmaking project in terms of collaboration, sponsorship or general input, please reach out to Connor Haslem at: Connor@microdose.buzz

MagicMed Industries Inc. announced that it has entered into a Research Contract and a Facilities Use Agreement with the University of Calgary. The Agreements provide MagicMed with further scientific and laboratory support to accelerate development of its psychedelic derivatives patent library, the PsybraryTM.

"The University of Calgary is excited to partner with MagicMed, an innovative company pursuing psychedelics research," says Associate Vice-President (Research – Innovation), Dr. Steve Larter. "Partnerships like this combine frontline discovery with providing real solutions to society and create opportunities for our researchers and students to help bring cutting-edge knowledge to market."

"The additional resources that the University of Calgary is providing to MagicMed compliment and enhance our strengths," says Dr. Joseph Tucker, CEO MagicMed. "This collaboration places MagicMed in a position to expand the breadth and depth of the psychedelic derivatives contained in the MagicMed PsybraryTM."

Through the Agreements, MagicMed will be able to leverage new state of the art equipment and laboratory space at the University of Calgary, as well as draw upon its world-class expertise. Laboratory and resource costs of the MagicMed PsybraryTM expansion will be efficiently allocated while development progress will be expedited.

Mind Medicine Inc. (NEO: MMED) (OTCQB: MMEDF) announced that it has closed its previously announced bought deal short form prospectus offering, including the exercise in full of the underwriter's over-allotment option. In connection with the Offering, the Company issued 27,381,500 units of the Company at a price per Unit of $1.05 for gross proceeds of $28,750,575. Canaccord Genuity Corp. acted as sole bookrunner and underwriter in the Offering.

Each Unit comprises one subordinate voting share of the Company and one-half of one Subordinate Voting Share purchase warrant. Each Warrant entitles the holder thereof to purchase one Subordinate Voting Share at an exercise price of $1.40 until October 30, 2023. The Warrants will be listed for trading on the facilities of the NEO Exchange Inc. under the symbol "MMED.WS", subject to the final approval of the NEO.

MindMed Co-Founder & Co-CEO, J.R. Rahn said "The strong institutional investor interest for this oversubscribed financing demonstrates the vast appetite for companies pursuing clinical trials of psychedelic medicines with the FDA and other regulatory bodies. With our sights set on a NASDAQ up-listing, this fresh funding will further assist the MindMed team in our mission to build the most diverse development pipeline of psychedelic inspired medicines and experiential therapies for patients."

Post-financing the Company now has cash reserves of CAD $50.1m (USD $37.8m) to enable continued progress of its clinical trial pipeline of psychedelic inspired medicines and experiential therapies.

The Company intends to use the net proceeds of the Offering for investment in its research and clinical development initiatives, including its 18-MC addiction treatment program derived from the psychedelic ibogaine, lysergic acid diethylamide (LSD) microdose program for Adult ADHD, Project Lucy focused on LSD experiential therapy for anxiety disorders, University Hospital Basel Liechti Lab research and development collaboration, its partnership with NYU Langone Health for a Psychedelic Medicine Research Training Program, and for general working capital and corporate development purposes.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.

MindMed is a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and experiential therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed team brings extensive biopharmaceutical experience to the Company's groundbreaking approach to developing the next generation of psychedelic inspired medicines and experiential therapies.

In closing today’s podcast if you are still on the fence about the benefits of psychedelic medicine (or cannabis) we’ve included two book recommendations that do an amazing job of illustrating the importance and necessity of whole plant based medicines in the modern world, especially in a COVID world.

The first is “Psychedelic Medicine: The Healing Powers of LSD, MDMA, Psilocybin, and Ayahuasca” which explores the potential of psychedelics as medicine and the intersections of politics, science, and psychedelics as well as offers non-technical summaries of the most recent, double-blind, placebo-controlled studies with MDMA, psilocybin, LSD, and ayahuasca. This book includes the work of Rick Doblin, Stanislav Grof, James Fadiman, Julie Holland, Dennis McKenna, David Nichols, Charles Grob, Phil Wolfson, Michael and Annie Mithoefer, Roland Griffiths, Katherine MacLean, and Robert Whitaker and is available on Amazon or if you’re in Canada, you can buy online from my local head shop Mary Jane’s HQ.

The second has garnered more controversy but is, in my opinion, a must read during this time in history particularly, is “Thus Spoke the Plant: A Remarkable Journey of Groundbreaking Scientific Discoveries and Personal Encounters with Plants” by Monica Gagliano. This book is both haunting and profound and offers a new perspective on plants, medicine and communication with nature in the modern world. This book is also available on Amazon and you listen to her in depth discussion on plant consciousness on Youtube to hear her words directly.

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

about Investorideas.com

About Investorideas.com - News that Inspires Big Investing Ideas